ERG and cancer: A refined analysis further revealed that the prognostic relevance of MTC02 was limited the 1,852 ERG-negative cancers lacking PTEN deletion (p < 0.0001; Figure 4E), while there was no effect in 249 ERG negative cancers harboring PTEN deletions (p = 0.2367; Figure 4F).